Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.52 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.48 |
| ▸ | CXCR3 | P49682 | 3/20 | 0.47 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.47 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.47 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.45 |
| ▸ | GPR183 | P32249 | 1/20 | 0.45 |
| ▸ | ACHE | P22303 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2930516 | 0.82 | KDM4E (0.50) | KDM4ESMN1; SMN2MCHR1CXCR3HDAC1 | |
| SCHEMBL2930518 | 0.82 | KDM4E (0.50) | KDM4ESMN1; SMN2MCHR1CXCR3HDAC1 | |
| SCHEMBL20210280 | 0.81 | KDM4E (0.59) | KDM4ESMN1; SMN2HDAC1HDAC6ALDH1A1 | |
| SCHEMBL20195981 | 0.80 | KDM4E (0.62) | KDM4ESMN1; SMN2ALDH1A1MEN1KMT2A | |
| SCHEMBL2933311 | 0.80 | ALDH1A1 (0.49) | KDM4EHDAC1HDAC6ALDH1A1HPGD | |
| SCHEMBL2929035 | 0.79 | ALDH1A1 (0.70) | KDM4EMCHR1HDAC1HDAC6GPR183 | |
| SCHEMBL31010076 | 0.79 | KDM4E (0.70) | KDM4ESMN1; SMN2CXCR3ALDH1A1MEN1 | |
| Hydrochloric Acid SCHEMBL23850500 | 0.76 | CXCR3 (0.65) | KDM4ESMN1; SMN2CXCR3GPR183ALDH1A1 | |
| SCHEMBL3872686 | 0.75 | DRD2 (0.68) | MCHR1 | |
| Ammonia Solution, Strong SCHEMBL2927635 | 0.75 | KDM4E (0.55) | KDM4ESMN1; SMN2CXCR3ALDH1A1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2121616-B1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2010-09-15 | — | — | EP | disclosed |
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | GIUSEPPE CAMPIANI (IT) | 2010-04-15 | — | — | US | disclosed |
| EP-2121616-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | Campiani, Giuseppe (IT) | 2009-11-25 | — | — | EP | disclosed |
| WO-2008101891-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | CAMPIANI GIUSEPPE (IT) | 2008-08-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100093726-A1 | NOVEL 4-AMINO-QUINOLINE DERIVATIVES USEFUL AS ANTI-MALARIA DRUGS | QTRT1, QTRT2, IL4I1 | KDM4E 315/4885SMN1; SMN2 4673/4885MCHR1 3775/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.